Follitropin Alfa: 5 agencies, 2004–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 17.8 years separate the first record, 18 Mar 2004 at TLV (Sweden), from the most recent, 15 Dec 2021 at HAS (France).
TLV (Sweden) changed its position: recommended on 18 Mar 2004, restricted by 23 Mar 2020.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
6 distinct indication wordings are recorded for follitropin alfa by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess follitropin alfa, on 18 Mar 2004; PBAC (Australia) did not open a file until 2018 — an unusually long tail of 14.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
4 of the 5 agencies here assessed follitropin alfa more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed follitropin alfa.
The full ledger for follitropin alfa reads 8 recommended, 2 not recommended, 2 restricted and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 15 Dec 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2021 | Assisted reproductive technology | Not Recommended | source |
| TLV (Sweden) | 23 Mar 2020 | Ovaleap ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 6 Dec 2016 | Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citr… | outside AWMSG criteria | source |
| SMC (Scotland) | 9 Feb 2015 | In adult women for: anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate; stimulation of multi-fol… | accepted | source |
8 further decisions for follitropin alfa, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- follitropin delta — divergent outcome (recommended vs restricted) on a shared indication
- choriogonadotropin alfa — same ATC class G03G — Sex hormones and modulators
- tocilizumab — also decided by HAS in 2021Q4
- cannabidiol — also decided by HAS in 2021Q4
- vosoritide — also decided by HAS in 2021Q4
- ipilimumab — also decided by HAS in 2021Q4
Coverage: 13 decisions for follitropin alfa from 5 agencies, 2004 to 2021. Data to 7 Sep 2026. ATC class G03G — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.